Takeda Spotlights Three Late-Stage Readouts as Potential "Inflection Point" Amid Vyvanse Generic Competition
Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.
AbbVie and Galapagos Form $406 Million Alliance to Develop Novel Cystic Fibrosis Therapies
AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients.
© Copyright 2025. All Rights Reserved by MedPath